Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling

Breast Cancer Research

Timothy G Cooke¹  Jonathan R Reeves¹  Peter D Stanton¹  John MS Bartlett¹  Caroline J Witton¹  Sian M Tovey¹ 

[1] Endocrine Cancer Group, Division of Cancer Sciences and Molecular Biology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK

关键词: HER4;    HER3;    HER2;    HER1;    bromodeoxyuridine;    breast cancer;   

Others  :  1118764
DOI  :  10.1186/bcr783

 received in 2003-11-27, accepted in 2004-03-04,  发布年份 2004

【 摘 要 】

Background

We have shown previously that whilst overexpression of HER1, 2 and 3 is associated with poor prognosis in breast cancer, HER4 is associated with a good prognosis. Cell proliferation is a key component of aggressive cancers and is driven by growth factors. In this study bromodeoxyuridine-derived proliferation indices are correlated with clinical outcome and HER1-4 status to further clarify the differing roles for the HER family at a biological level.

Patients and Methods

78 invasive breast cancers had BrdU in vivo labelling to determine the labelling index (BLI) and the potential tumour doubling time (T_pot). Long term clinical follow up was available for these patients. Using immunohistochemistry we established the HER1-4 status in 55 patients from the BrdU cohort.

Results

We demonstrate a significant correlation between high BLI values and breast cancer specific death (p = 0.0174). Low T_pot times were also significantly correlated with breast cancer specific death (p = 0.0258). However BLI did not independently predict survival in Cox's multiple regression analysis when combined with other prognostic factors such as size, grade and nodal status.

Tumours found to be positive for HER 1, 2 or 3 had significantly (p = 0.041) higher labelling indices, with HER1 also showing significantly higher indices when considered independently (p = 0.024). Conversely HER4 positivity significantly correlated (p = 0.013) with low BLI values in line with previous data associating this receptor with good prognosis tumours.

Conclusions

These results support the hypothesis that HER1-3 are associated with driving tumour proliferation whilst HER4 is involved in a non-proliferative or even protective role.

   

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Amadori D, Silvestrini R: Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat 1998, 51:267-281.
• [2]Rew DA, Wilson GD: Cell production rates in human tissues and tumours and their significance. Part 1: an introduction to the techniques of measurement and their limitations. Eur J Surg Oncol 2000, 26:227-238.
• [3]Goodson WH III, Moore DH, Ljung BM, Chew K, Mayall B, Smith HS, Waldman FM: The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat 2000, 59:113-123.
• [4]Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
• [5]Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 1992, 66:1116-1121.
• [6]Sainsbury JR, Farndon JR, Sherbet GV, Harris AL: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1985, 1:364-366.
• [7]Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25.
• [8]Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
• [9]Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297.
• [10]Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410:83-86.
• [11]Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13:3-17.
• [12]Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16:413-428.
• [13]Cooke T, Reeves J, Lannigan A, Stanton P: The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001, 37(Suppl 1):3-10.
• [14]Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987, 1:1398-1402.
• [15]Naidu R, Yadav M, Nair S, Kutty MK: Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998, 78:1385-1390.
• [16]Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO: C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996, 74:229-233.
• [17]Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000, 6:4217-4225.
• [18]Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA: c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 1994, 25:247-252.
• [19]Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW, Robertson JF, Nicholson RI: c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998, 17:1949-1957.
• [20]Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25.
• [21]Stanton PD, Cooke TG, Forster G, Smith D, Going JJ: Cell kinetics in vivo of human breast cancer. Br J Surg 1996, 83:98-102.
• [22]Frierson HF Jr: Ploidy analysis and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. Am J Surg Pathol 1991, 15:358-367.
• [23]Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP: The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 1984, 33:441-445.
• [24]Cooke TG, Stanton PD, Winstanley J, Murray GD, Croton R, Holt S, George WD: Long-term prognostic significance of thymidine labelling index in primary breast cancer. Eur J Cancer 1992, 28:424-426.
• [25]Stanton PD, Cooke TG, Oakes SJ, Winstanley J, Holt S, George WD, Murray GD: Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br J Cancer 1992, 66:925-929.
• [26]Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
• [27]Begg AC, McNally NJ, Shrieve DC, Karcher H: A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985, 6:620-626.
• [28]White RA, Terry NH, Meistrich ML, Calkins DP: Improved method for computing potential doubling time from flow cytometric data. Cytometry 1990, 11:314-317.
• [29]Cutress RI, Mullee MA, Royle GT, Rew DA: Clinical outcome and bromodeoxyuridine-derived proliferation indices in 75 invasive breast carcinomas. Eur J Surg Oncol 2000, 26:747-750.
• [30]van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van d V, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
• [31]Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 1996, 56:3823-3830.
• [32]Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993, 29A:1018-1023.
• [33]Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, Moch H, Gudat F, Mihatsch MJ, Waldman F: Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 1994, 57:508-514.
• [34]Moriki T, Takahashi T, Kataoka H, Hiroi M, Yamane T, Hara H: Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathol Int 1996, 46:953-961.
• [35]Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ: The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res 1996, 16:3141-3147.
• [36]Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001, 61:8452-8458.
• [37]Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME: Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999, 59:5315-5322.
• [38]Wang LM, Kuo A, Alimandi M, Veri MC, Lee CC, Kapoor V, Ellmore N, Chen XH, Pierce JH: ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc Natl Acad Sci U S A 1998, 95:6809-6814.
• [39]Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS III: Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001, 21:4265-4275.
• [40]Jones FE, Welte T, Fu XY, Stern DF: ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 1999, 147:77-88.
• [41]Gullick WJ: c-erbB-4/HER4: friend or foe? J Pathol 2003, 200:279-281.
• [42]Baselga J: Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001, 61(Suppl 2):14-21.